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In the 1890s, William Coley, a New York City surgeon,
obtained spectacular results in some patients with sarco-
ma after inoculating their tumors with the erysipelas-
causing bacteria. Since then, many cancer researchers
have dreamt of developing therapies based on the exquisite
specificity of the immune system to eliminate tumors
without the toxicity associated with chemo and/or radiation
therapy.
Currently, 120 years later, the list of accomplishments
in this area begins to grow:
1. Three cytokines are used in anticancer therapies: high
dose IL-2 in advanced melanoma and metastatic renal
cancer, Interferon-α for hairy cell leukemia and as
adjuvant therapy in melanoma in high risk of relapse,
and the TNF-α for treatment of loco-regional disease,
via extracorporeal perfusion, in melanoma and sarco-
ma.
2. It has been shown that Bacille Calmette-Guérin (BCG)
instillation is an efficient treatment in recurrent super-
ficial bladder carcinoma.
3. There are over a dozen monoclonal antibodies that are
used in treating diverse types of tumors; of these,
rituximab is considered an example of immune therapy
because it targeteds the CD20 molecule expressed in
the B lymphocytes and is useful in treating B-cell
lymphoma.
4. The first therapeutic-cancer vaccine was approved in
the United States by the Food and Drug Administration
(FDA) in 2009. It is a recombinant protein representing
a prostate-associat antigen Prostate Acid Phosphatase,
(PAP) that must be loaded onto autologous dendritic
cells prior to their infusion into the bloodstream.
5. Finally, in March 2011, the FDA approved the
monoclonal antibody that blocks the CTLA-4 inhibitory
receptor, which, when repeatedly administered,
duplicates the median survival time of patients with
advanced metastatic melanoma. It is the first treatment
in many decades that manages to prolong survival
rates in a type of cancer like malignant melanoma.
Hence, the study of the interactions between the
immune system and cancer has been a continuous source
of new anti-cancer therapies. The rate of discoveries has
accelerated considerably over the last 15 years, as well as
the rate of clinical trials to test new concepts and new
immunotherapeutic products. Scientists, important sectors
of big pharma and, most importantly, cancer patients,
share great optimism on new promising therapies based
on the immune system.
Conceptually, cancer immunotherapy rests on the
postulate of the immune surveillance of tumors. This was
clearly formulated in the 1950s by M. Burnet. This theory
has been received with a variety of attitudes ranging from
extreme enthusiasm to extreme skepticism. Nevertheless,
a considerable amount of experimental results obtained
from models of spontaneous tumors of growing
sophistication has come to conclusively test this hypothesis.
Currently, it is perfectly clear that the immune system
specifically recognizes tumors and the outcome of this
event is variable. In some cases, the immune system is
capable of suppressing the tumoral progression, resulting
in hidden, clinically silent tumors. In other cases, the
tumoral progression coincides with the induction of
specific immunological tolerance even during early stages
of carcinogenesis. In humans, numerous studies have
established the favorable prognosis associated with an
infiltration of primary tumors by abundant memory T
lymphocytes, particularly CD8 T lymphocytes. The likely
meaning of this strong correlation is that the T lymphocytes
that infiltrate the tumors represent a line of defense
against tumoral progression that can protect the patient
from a relapse during prolonged periods after surgical
excision of the tumoral mass.
Recent progress in immunology is shedding light on
the cellular and molecular mechanisms governing the
initiation and maintenance of T lymphocyte responses,
which protect the host from infections from viruses,
intracellular bacteria, and metazoan parasites, as well as
from tumors. A general model has gained wide acceptance
according to which the immune system has developed
mechanisms that permit it to recognize molecular patterns
specifically associated with pathogenic microorganisms,
as well as cell and tissue damage. It has also generated
extremely specific systems allowing efficient discri-
mination between autologous and foreign components at
the level of each cell of the economy. The specific
recognition systems are the antibodies, capable of
recognizing antigens in solution and the T lymphocytes
equipped with T-cell antigen receptors (TCR) capable of
recognizing internal antigens associated with the antigens
of the major histocompatibility complex. According to
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this model, the expectation was that tumor antigens
recognized by the lymphocytes infiltrating the tumors
should be derived from oncogenic viruses or from
somatically mutated genes generated during of
carcinogenesis.  For this reason, there was general surprise
when it became evident that most tumor antigens are
actually self-antigens, derived from normal proteins. There
are currently hundreds of tumor antigens identified, which
are none other than combinations of short peptides derived
generally from non-mutated proteins (10-25 amino acids)
and class I HLA molecules (-A,- B, or -C) or class II (-DR,
-DP, or -DQ). The former are recognized by CD8 T
lymphocytes with cytolytic capacity and the latter  by CD4
T lymphocytes capable of multiple immunoregulatory
functions.
Knowledge  on the identity of tumor antigens has
opened new avenues of research. First, it has enabled
monitoring of the anti-tumoral responses of T lymphocytes
in cancer patients. A considerable wealth of information
has been accumulated, which allows understanding the
dynamics of these responses and understanding the reasons
why tumors progress in spite of the presence of anti-
tumoral immune responses. Second, the scientific
community has embarked on the vigorous search for
therapeutic vaccines against cancer. In this case, certain
tumor antigens are selected as targets in the design of
anticancer vaccine candidates. Until now, hundreds of
phase I and II clinical trials have been conducted to test the
safety and tolerance of new therapeutic vaccines. Two
promising vaccines (MAGE-A3 and MUC-1) are being
currently evaluated in terms of their clinical efficiency in
treating lung cancer and metastatic melanoma, in
randomized, double blind, placebo controlled phase III
clinical trials. Third, this information has also inspired the
optimization of novel cellular therapies consisting of ex
vivo expansion of tumor-infiltrating T lymphocytes for a
subsequent reinfusion of massive numbers (billions) of
these cells. It is also possible to «reprogram» autologous
T lymphocytes via transduction with a retroviral vector
that carries TCRs specific for defined tumor antigens.
At the forefront of basic research, interest centers on
understanding the multiple mechanisms operating inside
the tumors and which impede an efficient anti-tumoral
immune response. New targets have been identified for
future therapies that should neutralize these immune-
suppressing circuits and, thus, enhance the anti-tumoral
response. Among these, there are inhibiting receptors
such as CTLA-4, PD-1, Tim-3, BTLA, CD4 regulatory T
lymphocytes, or myeloid derived suppressor cells.s
Certain enzymes are expressed at excessively high
levels in the tumor microenvironment like Cox-2, IDO,
INOS, and arginase. Their activity suppresses (for different
reasons) the anti-tumoral immune response. Their
inhibition in experimental tumor models has revealed a
clear therapeutic potential. Finally, components of tumor
stroma such as activated fibroblasts or blood neovessels
are also valuable therapeutic targets.
In conclusion, cancer immunotherapy is an area
undergoing development. Recently, new therapies have
come about based on harnessing the immune system and
it should be expected that in the future the number and
efficiency of the new anti-cancer immune-therapies will
continue to expand significantly.
In light of this, it is worth wondering how to prepare
the medical and cancer patient communities for the new
realities associated with the surge of these new therapies
at the national level. It would also be worthwhile to
address the Colombian scientific community about their
attitude and willingness to participate in these latest
developments.
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